GlassScriptPhysician profile
Naomi Flock
NPI 1164840351
$2,768.42
in general payments reported to CMS, 2019-2025
26 companies · $580 in 2025
The $580 reported for 2025 was more than what 77% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.29 · 2020: $31.10 · 2021: $332 · 2022: $409 · 2023: $772 · 2024: $632 · 2025: $580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,984.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,983.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $492.74 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $479.05 | 2021-2025 | |
| Glaxosmithkline, LLC. | $421.97 | 2020-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Abbvie INC. | $229.10 | 2021-2024 | |
| Phathom Pharmaceuticals, INC. | $182.67 | 2024-2025 | Voquezna |
| Renalytix Ai, INC. | $135.58 | 2023-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Bayer Healthcare Pharmaceuticals INC. | $112.92 | 2023-2025 | |
| Corium, LLC | $86.60 | 2023 | Azstarys |
| Amgen INC. | $78.68 | 2024-2025 | Repatha, Otezla, Prolia |
| Exact Sciences Corporation | $74.23 | 2023-2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $54.04 | 2021-2022 | |
| Myriad Women'S Health, INC. | $52.83 | 2023 | Myrisk |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.98 | 2021-2022 | |
| Lilly USA, LLC | $40.95 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Otsuka America Pharmaceutical, INC. | $37.82 | 2024-2025 | Rexulti |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.36 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $34.26 | 2022-2025 | Airsupra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.79 | 2025 | Caplyta |
| Dynavax Technologies Corporation | $24.90 | 2023 | Heplisav-B |
| Abbott Laboratories | $21.23 | 2022 | |
| Daiichi Sankyo INC. | $19.15 | 2022 | |
| Hologic Sales and Service, LLC | $18.07 | 2020 | |
| Medtronic, INC. | $15.82 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.43 | 2024 | Xarelto |
| Organon LLC | $14.96 | 2023 | Nexplanon |
| Gilead Sciences, INC. | $12.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naomi Flock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.